Pathogenesis of amyotrophic lateral sclerosis

British Medical Bulletin

Volumn 119, Issue 1, 2016, Pages 87-97

  Morgan, Sarah ^a   Orrell, Richard W ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

amyotrophic lateral sclerosis; genetics; pathogenesis; treatment

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; GROWTH FACTOR; MYOGENIC FACTOR; TAR DNA BINDING PROTEIN; ANTICONVULSIVE AGENT; C9ORF72 PROTEIN, HUMAN; DNA BINDING PROTEIN; FUS PROTEIN, HUMAN; PROTEIN; RILUZOLE; RNA BINDING PROTEIN FUS; SOD1 PROTEIN, HUMAN; TDP-43 PROTEIN, HUMAN;

AMYOTROPHIC LATERAL SCLEROSIS; ASSISTED VENTILATION; CLINICAL FEATURE; EPIGENETICS; EXCITOTOXICITY; GENETIC ANALYSIS; HEREDITY; HUMAN; INFLAMMATION; LIPOSARCOMA; MITOCHONDRION; NERVE DEGENERATION; NERVE FIBER TRANSPORT; NONHUMAN; NUTRITIONAL SUPPORT; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW; RNA PROCESSING; SARCOMA; DRUG EFFECTS; EXECUTIVE FUNCTION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; MOLECULARLY TARGETED THERAPY; MUTATION; ONSET AGE; PATHOLOGY; PATHOPHYSIOLOGY; TRENDS;

AGE OF ONSET; AMYOTROPHIC LATERAL SCLEROSIS; ANTICONVULSANTS; DNA-BINDING PROTEINS; EXECUTIVE FUNCTION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; PROTEINS; RILUZOLE; RNA-BINDING PROTEIN FUS; SUPEROXIDE DISMUTASE-1;

EID: 84994137659     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldw026     Document Type: Review

References (58)

1. Al-Chalabi A, Calvo A, Chio A, et al. Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol 2014;13:1108-13.
2. Al-Chalabi A and Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol 2013;9:617-28.
3. Al-Chalabi A, Fang F, Hanby MF, et al. An estimate of amyotrophic lateral sclerosis heritability using twin data. J Neurol Neurosurg Psychiatry 2010;81:1324-6.
4. Keller MF, Ferrucci L, Singleton AB, et al. Genomewide analysis of the heritability of amyotrophic lateral sclerosis. JAMA Neurol 2014;71:1123-34.
5. Su XW, Broach JR, Connor JR, et al. Genetic heterogeneity of amyotrophic lateral sclerosis: implications for clinical practice and research. Muscle Nerve 2014;49:786-803.
6. Renton AE, Chio A and Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 2014;17:17-23.
7. Majounie E, Renton AE, Mok K, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol 2012;11:323-30.
8. Ogaki K, Li Y, Atsuta N, et al. Analysis of C9orf72 repeat expansions in 563 Japanese patients with amyotrophic lateral sclerosis. Neurobiol Aging 2012;33:2527. e11-16.
9. Chen Y, Lin Z, Chen Z, et al. Large C9orf72 repeat expansions are seen in Chinese patients with sporadic amyotrophic lateral sclerosis. Neurobiol Aging 2016;38:217.e15-22.
10. Rohrer JD, Isaacs AM, Mizielinska S, et al. C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis. Lancet Neurol 2015;14:291-301.
11. Gijselinck I, Van Mossevelde S, van der Zee J, et al. The C9orf72 repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter. Mol Psychiatry 2015 epub.
12. Bennion Callister J and Pickering-Brown SM. Pathogenesis/genetics of frontotemporal dementia and how it relates to ALS. Exp Neurol 2104;262:84-90.
13. Gendron TF, Belzil VV, Zhang Y-J, et al. Mechanisms of toxicity in C9FTLD/ALS. Acta Neuropathol 2014; 127:359-76.
14. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362:59-62.
15. Chio A, Traynor BF, Lombardo F, et al. Prevalence of SOD1 mutations in the Italian ALS population. Neurology 2008;70:533-7.
16. Lattante S, Rouleau GA and Kabashi E. TARDBP and FUS mutations associated with amyotrophic lateral sclerosis: summary and update. Hum Mutat 2013;34:812-26.
17. Deng H, Gao K and Jankovic J. The role of FUS gene variants in neurodegenerative diseases. Na Rev Neurol 2014;10:337-48.
18. Leblond CS, Kaneb HM, Dion PA, et al. Dissection of genetic factors associated with amyotrophic lateral sclerosis. Exp Neurol 2014;262:91-101.
19. Cady J, Allred P, Bali T, et al. Amyotrophic lateral sclerosis onset is influenced by the burden of rare variants in known amyotrophic lateral sclerosis genes. Ann Neurol 2015;77:11-113.
20. Morgan S, Shoai M, Fratta P, et al. Investigation of next-generation sequencing technologies as a diagnostic tool for amyotrophic lateral sclerosis. Neurobiol Aging 2015;36:1600.e5-8.
21. Paez-Colasante X, Figueroa-Romero C, Sakowski SA, et al. Amyotrophic lateral sclerosis: mechanisms and therapeutics in the epigenomic era. Nat Rev Neurol 2015;11:266-79.
22. Ravits J. Focality, stochasticity and neuroanatomic propagation in ALS pathogenesis. Exp Neurol 2014;262:121-26.
23. Braak H, Brettschneider J, Ludolph AC, et al. Amyotrophic lateral sclerosis-a model of corticofugal axonal spread. Nat Rev Neurol 2013;9:708-14.
24. Sekiguchi T, Kanouchi T, Shibuya K, et al. Spreading of amyotrophic lateral sclerosis lesions-multifocal hits and local propagation? J Neurol Neurosurg Psychiatry 2014;85:85-91.
25. Menke RA, Korner S, Filippini N, et al. Widespread grey matter pathology dominates the longitudinal cerebral MRI and clinical landscape of amyotrophic lateral sclerosis. Brain 2014;137:2546-55.
26. Pupillo E, Messina P, Giussani G, et al. Physical activity and amyotrophic lateral sclerosis: a European population-based case-control study. Ann Neurol 2014;75:708-16.
27. McKee AC, Gavett BE, Stern RA, et al. TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol 2010; 69:918-29.
28. Ingre C, Roos PM, Piehl F, et al. Risk factors for amyotrophic lateral sclerosis. Clin Epidemiol 2015;7:181-93.
29. Shang H, Liu G, Jiang Y, et al. Pathway analysis of two amyotrophic lateral sclerosis GWAS highlights shared genetic signals with Alzheimers Disease and Parkinsons disease. Mol Neurobiol 2015;51:361-9.
30. Beck J, Poulter M, Hensman D, et al. Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population. Am J Hum Genet 2013;92:345-53.
31. Peters OM, Ghasemi M and Brown RH Jr.. Emerging mechanism of molecular pathology in ALS. J Clin Invest 2015;125:1767-79.
32. Gascon E and Gao FB. The emerging roles of microRNAs in the pathogenesis of frontotemporal dementia-amyotrophic lateral sclerosis (FTD-ALS) spectrum disorders. J Neurogenet 2014;28:30-40.
33. Kepp KP. Genotype-property patient-phenotype relations suggest that proteome exhaustion can cause amyotrophic lateral sclerosis. PLoS One 2015;10:e0118649, doi:10.1371.
34. Palomo GM and Manfredi G. Exploring new pathways of neurodegeneration in ALS: the role of mitochondria quality control. Brain Res 2015;1607:36-46.
35. Tadic V, Prell T, Lautenschlaeger J, et al. The ER mitochondria calcium cycle and ER stress response as therapeutic targets in amyotrophic lateral sclerosis. Front Cell Neurosci 2014;8:147, doi:10.3389/fncel.2014.00147.
36. Tafuri F, Ronchi D, Magri F, et al. SOD1 misplacing and mitochondrial dysfunction in amyotrophic lateral sclerosis pathogenesis. Front Cell Neurosci 2015;9:336, doi:10.3389/fncel.2015.00336.
37. Le Masson G, Przedborksi S and Abbott LF. A computational model of motor neuron degeneration. Neuron 2014;83:975-88.
38. Bannwarth S, Ait-El-Mikadem S, Chaussenot A, et al. A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement. Brain 2014;137:2329-45.
39. Dimitriadi M, Kye MJ, Kalloo G, et al. The neuroprotective drug riluzole acts via small conductance Ca2+-activated K+ channels to ameliorate defects in spinal muscular atrophy models. J Neurosci 2013;33:6557-62.
40. Meininger V, Pradat PF, Corse A, et al. Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human trail. PLoS One 2014;9: e97803.
41. Grad LI, Fernando SM and Cashman NR. From molecule to molecule and cell to cell: prion-like mechanisms in amyotrophic lateral sclerosis. Neuroubiol Dis 2015;77:257-65.
42. Grad LI and Cashman NR. Prion-like activity of Cu/Zn superoxide dismutase: implications for amyotrophic lateral sclerosis. Prion 2014;8:33-41.
43. Brites D and Vaz AR. Microglia centered pathogenesis in ALS: insights in cell interconnectivity. Front Cell Neurosci 2014;8:117.
44. Valori CF, Brambilla L, Martorana F, et al. The multifaceted role of glial cells in amyotrophic lateral sclerosis. Cell Mol Life Sci 2014;71:287-97.
45. Boyer JG, Ferrier A and Kothray R. More than a bystander: the contributions of intrinsic skeletal muscle defects in motor neuron diseases. Front Physiol 2013;4:356.
46. Pansarasa O, Rossi D, Berardenilli A, et al. Amyotrophic lateral sclerosis and skeletal muscle: an update. Mol Neurobiol 2014;49:984-90.
47. Johnson JO, Mandrioli J, Benatar M, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 2010;68:857-64.
48. Muller TJ, Kraya T, Stoltenburg-Didinger G, et al. Phenotype of matrin-3-related distal myopathy in 16 German patients. Ann Neurol 2014;76:669-80.
49. Swinnen B and Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol 2014;10:661-70.
50. Millecamps S, Salachas F, Cazeneuve C, et al. SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype-phenotype correlations. J Med Genet 2010;47:554-60.
51. Goyal NA and Mozaffar T. Experimental trials in amyotrophic lateral sclerosis: a review of recently completed, ongoing and planned trials using existing and novel drugs. Expert Opin Investig Drugs 2014;23: 1541-51.
52. McGoldrick P, Joyce PI, Fisher EM, et al. Rodent models of amyotrophic lateral sclerosis. Biochim Biophys Acta 2013;1832:1421-36.
53. Poppe L, Rue L, Robberecht W, et al. Translating biological findings into new treatment strategies for amyotrophic lateral sclerosis (ALS). Exp Neurol 2014;262: 138-51.
54. Miller TM, Pestronk A, David W, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomized, first-in-man study. Lancet Neurol 2013;12:435-42.
55. Scarrott JM, Herranz-Martin S, Alrafiah AR, et al. Current developments in gene therapy for amyotrophic lateral sclerosis. Expert Opin Biol Ther 2015;15: 935-47.
56. Van den Heuvel DM, Harshnitz O, van den Berg LH, et al. Taking a risk: a therapeutic focus on ataxin-2 in amyotrophic lateral sclerosis? Trends Mol Med 2014;20:25-35.
57. Chio A, Battistini S, Calvo A, et al. Genetic counseling in ALS: facts, uncertainties and clinical suggestions. J Neurol Neurosurg Psychiatry 2014;85:478-85.
58. Traynor BJ. A roadmap for genetic testing in ALS. J Neurol Neurosurg Psychiatry 2014;85:476.